<DOC>
	<DOCNO>NCT00426049</DOCNO>
	<brief_summary>The purpose present study provide first in-human safety efficacy evaluation systemic oral anti-proliferative Everolimus therapy compare placebo patient treat bare metal stent significant coronary artery disease . The aim reduce Major Adverse Cardiac Events ( MACEs ) include death , coronary artery bypass grafting ( CABG ) target vessel , Q-wave non-Q-wave myocardial infarction , target lesion revascularization within first 6 month intervention . Additionally safety tolerability Everolimus select dose patient population analyze .</brief_summary>
	<brief_title>Systemic Treatment With Everolimus Prevention MACE After Bare Metal Stent Implantation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Males female , age &gt; 18 year . 2 . Patients coronary artery disease schedule coronary intervention bare metal stent placement treatment de novo first restenosis native coronary artery . 3 . Target lesion must native coronary vessel 2.25 â€“ 4.0 mm size . 4 . Target lesion less equal 25 mm length . 5 . Tandem lesion may include long : overall length less equal 25 mm tandem lesion treat one stent count one lesion . The following exclusion criterion must present Baseline visit 1 ( BL1 , Screening visit prior coronary intervention ) . If exclusion criterion occur afterwards , e.g. , coronary intervention , patient must exclude study . 1 . Target lesion reference vessel size le 2.25 4.0 mm diameter . 2 . Target lesion total occlusion locate bifurcation . 3 . Treatment affords implantation one stent per treat lesion . 4 . Target lesion already treat brachytherapy . 5 . Target lesion one follow criterion : Left main lesion Ostial lesion RCA Located less 2 mm origin LAD RCX . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Coronary artery disease</keyword>
	<keyword>Stents</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Coronary restenosis</keyword>
	<keyword>Safety</keyword>
</DOC>